Importantly, the dual PI3K/mTOR inhibitor, BEZ235, has displayed robust anti-PRKDC activities and inhibition of tumor growth in pre-clinical mouse models; CC-115 also has a similar mTOR/PRKDC dual inhibition activity [62–65]. The gene discussed is MTOR; the disease is neoplasm.